pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels
Explore this paper's citation graph
Summary
An R package called pRRophetic is created, allowing prediction of clinical drug response for many cancer drugs in a user-friendly R environment and showing that prediction of bortezomib sensitivity in multiple myeloma may be improved by training models on a large set of neoplastic hematological cell lines.
- Type
- article
- Published
- 2014-09-17
- Cited by
- 2,021
- References
- 5
- Access
- Open access
- OpenAlex
- https://openalex.org/W2075294566
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:14344142
Keywords
R package, Cancer cell lines, Pipeline (software), Bortezomib, Multiple myeloma
References
- Inconsistency in large pharmacogenomic studies
- Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines
- The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
Cited by
- Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab
- Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics.
- Computational models for predicting drug responses in cancer research
- Institutional Profile: Pharmacogenomic research in R Stephanie Huang Laboratory.
- Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies
- Open source machine-learning algorithms for the prediction of optimal cancer drug therapies
- Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome atlas tumor transcriptome profile
- Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data
- Identification of Distinct Immune Subtypes in Colorectal Cancer Based on the Stromal Compartment
- Identification of biomarkers for the transition from low-grade glioma to secondary glioblastoma by an integrated bioinformatic analysis.
- In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma
- Comprehensive Analysis of Prognostic Alternative Splicing Signatures in Oral Squamous Cell Carcinoma
- Screening and Identification of Key Biomarkers in Acquired Lapatinib-Resistant Breast Cancer
- Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma
- Identification and validation of a ferroptosis-related genes based prognostic signature for prostate cancer
- Landscape of active enhancers developed de novo in cirrhosis and conserved in hepatocellular carcinoma.
- DNA Repair-Based Gene Expression Signature and Distinct Molecular Subtypes for Prediction of Clinical Outcomes in Lung Adenocarcinoma
- Identification of Epithelial–Mesenchymal Transition-Related lncRNA With Prognosis and Molecular Subtypes in Clear Cell Renal Cell Carcinoma
- A ferroptosis-associated gene signature for the prediction of prognosis and therapeutic response in luminal-type breast carcinoma
- High expression of JAM2 indicates better prognosis and immunotherapy response in breast cancer
Related papers
- Effect of Bortezomib on serum cystatin-C in multiple myeloma
- Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.
- Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma.
- [Proteasome inhibitors in treatment of multiple myeloma].
- Bortezomib:a proteasome inhibitor in the treatment of multiple myeloma
- Mechanism of resistance to proteasome inhibitor bortezomib in multiple myeloma
- Blood distribution of bortezomib and its kinetics in multiple myeloma patients.
- Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.
- Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation
- [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].